James Hassard - 04 Mar 2024 Form 4 Insider Report for Crinetics Pharmaceuticals, Inc. (CRNX)

Role: Chief Commercial Officer
Signature: /s/ Marc Wilson, as attorney-in-fact
Issuer symbol: CRNX
Transactions as of: 04 Mar 2024
Net transactions value: $0
Form type: 4
Filing time: 06 Mar 2024, 20:18:41 UTC
Previous filing: 03 Mar 2023
Next filing: 20 Mar 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CRNX	Common Stock	Award	$0	+17,000	+121%	$0.000000	31,000	04 Mar 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	CRNX	Stock Option (right to buy)	Award	$0	+63,000		$0.000000	63,000	04 Mar 2024	Common Stock	63,000	$43.51	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on March 15, 2025.
F2	The stock option shall vest and become exercisable in a series of forty-eight (48) successive equal monthly installments measured from the vesting commencement date of March 4, 2024.